Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy save search
Labcorp Launches Companion Diagnostic for Amgen’s Newly-approved Lung Cancer Therapy
Published: 2021-07-01 (Crawled : 00:00) - biospace.com/
LH M | $199.45 -0.26% 0.0% 770K
|
Health Services
|
| O: 0.36%
H: 0.61%
C: 0.42%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.0%
H: 1.38%
C: 1.3%
lung cancer therapy cancer approval diagnostic
Brookdale Completes Previously Announced Sale of a Majority Stake in its Home Health, Hospice and Outpatient Therapy Business to HCA Healthcare
Published: 2021-07-01 (Crawled : 21:00) - prnewswire.com
BKD | $6.52 0.93% 2.91% 1.4M
|
Health Services
|
| O: 0.0%
H: 1.84%
C: 0.86%
therapy
The Worldwide Radiotherapy Industry is Expected to Reach $7.3 Billion by 2026 at a CAGR of 4.2% from 2021
Published: 2021-07-01 (Crawled : 13:00) - prnewswire.com
BDX | $233.15 0.41% -0.86% 650K
|
Health Technology
|
| O: -0.07%
H: 1.66%
C: 1.55%
VRAY | $0.025 -39.9% -61.87% 110M
|
Health Technology
|
| O: 0.61%
H: 0.68%
C: -0.15%
ARAY | $2.21 0.91% 0.9% 690K
|
Health Technology
|
| O: 0.88%
H: 1.97%
C: -0.22%
therapy iot
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
Published: 2021-07-01 (Crawled : 06:00) - globenewswire.com
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 5.01%
H: 0.43%
C: -6.94%
gene therapy therapy collaboration announces collaboration gene therapies commercialization hereditary angioedema
Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases
Published: 2021-06-30 (Crawled : 21:00) - globenewswire.com
BEAM | $24.31 0.08% 1.7M
|
Health Technology
|
| O: 0.58%
H: 5.66%
C: 3.2%
APLS | $47.51 -1.08% -1.09% 1.6M
|
Health Technology
|
| O: 1.27%
H: 7.16%
C: 5.94%
disease collaboration research therapy
Scopus BioPharma Expands Immunotherapy Pipeline with Acquisition of Olimmune
Published: 2021-06-30 (Crawled : 14:00) - globenewswire.com
SCPS | $0.1682
|
|
| O: 1.26%
H: 4.43%
C: -1.11%
immunotherapy biopharma acquisition therapy expansion
Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma
Published: 2021-06-30 (Crawled : 13:00) - biospace.com/
ALLO | $3.46 -1.43% -1.59% 1.2M
|
Health Technology
|
| O: 0.44%
H: 4.62%
C: 3.08%
treatment fda fda fast track fast track therapy fast track designation t-cell designation
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer Company reaches important milestone to advance potential novel therapy for this subset of gastrointestinal cancers
Published: 2021-06-29 (Crawled : 17:00) - biospace.com/
RFL 4 | $1.71 -3.93% 0.0% 11K
|
Finance
|
| O: 0.31%
H: 3.04%
C: -2.82%
treatment fda potential test therapy cancer gastrointestinal drug cpi-613 milestone designation
Eli Lilly’s Antibody Therapy for COVID-19 Paused in US and More COVID-19 News
Published: 2021-06-29 (Crawled : 16:00) - biospace.com/
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: -0.01%
H: 0.39%
C: 0.02%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.01%
H: 1.38%
C: 0.49%
covid therapy antibody covid-19
Global Gene Therapy Market to Reach $2.7 Billion by 2026
Published: 2021-06-29 (Crawled : 14:15) - prnewswire.com
QURE | $4.71 0.86% 0.85% 440K
|
Health Technology
|
| O: 0.1%
H: 1.22%
C: -0.26%
SRPT | $116.55 -1.14% -1.12% 500K
|
Health Technology
|
| O: 0.0%
H: 0.25%
C: -2.43%
SGMO | $0.4851 -5.99% -6.33% 1.6M
|
Health Technology
|
| O: -0.91%
H: 1.08%
C: -2.66%
RGNX | $16.11 -5.4% -5.91% 560K
|
Health Technology
|
| O: -0.26%
H: 1.59%
C: -1.13%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 1.13%
H: 0.1%
C: -8.26%
NTLA | $21.32 -0.84% -0.94% 900K
|
Health Technology
|
| O: -2.19%
H: 17.95%
C: 16.17%
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: -0.04%
H: 0.53%
C: 0.38%
EDIT | $5.55 -1.07% -0.9% 1.3M
|
Health Technology
|
| O: 2.07%
H: 3.99%
C: 2.67%
CRSP M | $56.16 1.08% 1.03% 1.6M
|
Health Technology
|
| O: -0.41%
H: 1.48%
C: -0.34%
BLUE | $0.953 -1.07% -0.52% 6.2M
|
Health Technology
|
| O: -0.26%
H: 0.64%
C: -3.25%
AGTC | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 1.49%
H: 0.0%
C: -2.44%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: 0.42%
H: 0.15%
C: -0.62%
ADAP | $0.8984 -8.98% -9.86% 3.3M
|
Health Technology
|
| O: -0.68%
H: 1.6%
C: 0.23%
ABEO | $7.53 -5.04% -5.03% 250K
|
Health Technology
|
| O: 0.0%
H: 0.59%
C: -2.96%
gene therapy therapy gene therapies market
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License ApplicationCompany Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
VCEL | $43.86 -5.19% -5.47% 430K
|
Health Technology
|
| O: -15.34%
H: 4.46%
C: 0.63%
MDWD | $16.99 -2.58% -2.95% 42K
|
Health Technology
|
| O: -33.51%
H: 14.13%
C: 8.53%
fda potential therapy license approval
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
Published: 2021-06-29 (Crawled : 12:15) - biospace.com/
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: 0.0%
H: 0.32%
C: -0.2%
satellite treatment rosa europe therapy cancer colorectal cancer approval nivolumab
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
Published: 2021-06-29 (Crawled : 12:00) - biospace.com/
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 1.13%
H: 0.1%
C: -8.26%
gene therapy therapy gene therapies
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2021-06-29 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% -0.54% 3.4M
|
Health Technology
|
| O: 0.18%
H: 0.43%
C: 0.27%
europe therapy cancer her2+ keytruda her2- her2
The Power of Immersion Therapy
Published: 2021-06-28 (Crawled : 20:00) - middleby.com
MIDD | $141.01 -0.18% -0.16% 210K
|
Producer Manufacturing
|
| O: 0.69%
H: 0.69%
C: -1.13%
therapy
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
Published: 2021-06-28 (Crawled : 16:00) - biospace.com/
CVM | $1.5 5.33% 140K
|
Health Technology
|
| O: 7.26%
H: 1.41%
C: -49.11%
immunotherapy therapy cancer phase 3 iot cel
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
Published: 2021-06-28 (Crawled : 13:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: 0.62%
H: 0.5%
C: -0.88%
stem cell therapy t-cell car-t
Atsena Therapeutics Receives Orphan Drug Designation from the FDA for Novel Gene Therapy to Treat Genetic Eye Disease LCA1Phase I/II clinical trial is ongoing in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D
Published: 2021-06-28 (Crawled : 13:00) - biospace.com/
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.34%
H: 0.47%
C: 0.24%
disease fda genetic ongoing eye gene therapy therapy eye disease drug trial gene therapies designation
KidneyIntelX™ Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
RNLX | $0.785 -5.42% -2.34% 210K
|
Technology Services
|
| O: 0.32%
H: 0.03%
C: -2.3%
risk therapy response
Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcinoma
Published: 2021-06-28 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.53%
H: 0.38%
C: -0.34%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 1.49%
H: 0.16%
C: -2.85%
china therapy injection approval biosimilar
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.